GS XJG (Tykerb 250 mg)
Generic Name: lapatinib
Pill imprint GS XJG has been identified as Tykerb 250 mg.
Tykerb is used in the treatment of breast cancer, metastatic; breast cancer and belongs to the drug classes EGFR inhibitors, HER2 inhibitors. There is positive evidence of human fetal risk during pregnancy. Tykerb 250 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Generic Name:
- lapatinib
- Imprint:
- GS XJG
- Strength:
- 250 mg
- Color:
- Orange
- Shape:
- Elliptical / Oval
- Availability:
- Prescription only
- Drug Class:
- EGFR inhibitors
HER2 inhibitors - Pregnancy Category:
- D - Positive evidence of risk
- CSA Schedule:
- Not a controlled drug
- Manufacturer:
- GlaxoSmithKline
- National Drug Code (NDC):
- 00173-0752
- Inactive Ingredients:
- magnesium stearate
microcrystalline cellulose
povidone
sodium starch glycolate type A potato
FD&C Yellow No. 6
hypromelloses
polyethylene glycol
polysorbate 80
titanium dioxide
More about Tykerb (lapatinib)
Consumer resources
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
